Celloscope
Celloscope30About
What does Celloscope do?
Celloscope aimed to revolutionize digital health by transforming smartphones into personal health monitors. Utilizing advanced sensor and AI technologies, the company intended to detect medical emergencies and provide immediate guidance to users until professional medical help arrived.
What is Celloscope's revenue?
StartupHub estimates Celloscope's annual revenue at $386K (range $344K to $924K, 67% confidence), based on comparable companies in the sector.
When was Celloscope founded?
Celloscope was founded in 2018.
What industry does Celloscope operate in?
Celloscope operates in Healthcare, Monitor, HealthTech, MedTech, Digital Health, Wearables.
How many employees does Celloscope have?
Celloscope has approximately 2 people on record.
What is Celloscope's current status?
Celloscope's current operating status is: Inactive.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.